EKTA B logo

Elekta AB (publ) Stock Price

OM:EKTA B Community·SEK 20.8b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 18 Fair Values set on narratives written by author

EKTA B Share Price Performance

SEK 54.45
8.47 (18.42%)
SEK 58.27
Fair Value
SEK 54.45
8.47 (18.42%)
6.6% undervalued intrinsic discount
SEK 58.27
Fair Value
Price SEK 54.45
AnalystConsensusTarget SEK 58.27
AnalystHighTarget SEK 87.27
AnalystLowTarget SEK 39.00

EKTA B Community Narratives

AnalystConsensusTarget·
Fair Value SEK 58.27 6.6% undervalued intrinsic discount

European Launches And Chinese Recovery Will Expand Precision Radiotherapy Adoption

0users have liked this narrative
0users have commented on this narrative
12users have followed this narrative
AnalystHighTarget·
Fair Value SEK 87.27 37.6% undervalued intrinsic discount

Adaptive Radiotherapy And AI Convergence Will Expand Emerging Markets

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AnalystLowTarget·
Fair Value SEK 39 39.6% overvalued intrinsic discount

Rising Trade Barriers And Competition Will Squeeze MedTech Margins

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
SEK 87.27
37.6% undervalued intrinsic discount
Profit Margin
11.58%
Future PE
16x
Price in 2029
SEK 105.67

Trending Discussion

Updated Narratives

EKTA B logo

EKTA B: Future Outlook Balances Mixed Ratings With Product Adoption Progress

Fair Value: SEK 58.27 6.6% undervalued intrinsic discount
12 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
EKTA B logo

EKTA B: Rising Margin Outlook And New Clearance Will Support Medium Term Upside

Fair Value: SEK 87.27 37.6% undervalued intrinsic discount
0 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
EKTA B logo

EKTA B: FX And Tariffs Will Continue To Pressure Future Earnings

Fair Value: SEK 39 39.6% overvalued intrinsic discount
0 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Undervalued with reasonable growth potential and pays a dividend.

2 Risks
3 Rewards

Elekta AB (publ) Key Details

SEK 17.1b

Revenue

SEK 10.5b

Cost of Revenue

SEK 6.6b

Gross Profit

SEK 6.6b

Other Expenses

-SEK 40.0m

Earnings

Last Reported Earnings
Jan 31, 2026
Next Reporting Earnings
May 28, 2026
-0.10
38.51%
-0.23%
78.3%
View Full Analysis

About EKTA B

Founded
1972
Employees
4438
CEO
Jakob Just-Bomholt
WebsiteView website
www.elekta.com

Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers linear accelerator and radiation therapy products comprising Elekta Unity for anatomy-specific MR imaging; Elekta Evo that delivers offline and online adaptive radiation therapy; Elekta Versa HD, a brain metastases solution; Elekta Harmony; and Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs, as well as quality assurance, and treatment and motion management solutions. It also provides stereotactic radiosurgery products, such as Elekta Esprit, a gamma knife system; and Leksell GammaPlan, a treatment planning and management software, as well as Elekta ONE, an oncology software suite. In addition, the company offers brachytherapy products, including Elekta Studio, an image-guided brachytherapy solution; ImagingRing for dynamic imaging; Oncentra Brachy, a smart tool that facilitates repetitive tasks; Elekta Xoft Axxent and electronic brachytherapy systems; Elekta Geneva, an applicator for cervical cancer patients; Elekta Flexitron afterloader for enabling the precise execution of all steps in the workflow; and Venezia applicator that enables the oncologist to treat locally advanced cervical cancer. Further, it provides Leksell Vantage Stereotactic System, a neurosurgery product; Elekta Kaiku for personalized cancer care; and veterinary radiation therapy solutions. Additionally, the company offers Elekta Care support services; Elekta Care 360, which provides a range of clinical and professional services; Elekta Care Learning that offers in-person and digital training courses on radiotherapy; Elekta Care Community, a self-help center; Elekta Partner Community, an online self-service portal; and Elekta Intellimax for predictive maintenance. Elekta AB (publ) was incorporated in 1972 and is headquartered in Stockholm, Sweden.

Recent EKTA B News & Updates

Recent updates

No updates